Excalibur Fund Manager
Our current portfolio includes the following companies, click on a logo to visit the websites:
 | Ark Therapeutics Group plc Merlin Biosciences Fund Gene-based drugs for vascular and circulatory diseases and cancer IPO in March 2004 |
 | Biovertis AG Merlin Biosciences Fund Hospital-acquired infections; respiratory tract infections; urinary tract infections Acquired Morphochem AG in March 2006 |
 | Biovex Group Inc Merlin Biosciences Fund, Merlin Fund Development and commercialisation of biological treatments for cancer and the prevention of infectious disease |
 | Biowisdom Ltd Merlin Biosciences Fund III Knowledge management software for drug development |
 | Cyclacel Pharmaceutical Inc Merlin Biosciences Fund Cell cycle control drugs for cancer IPO in January 2006 |
 | Decon Sciences Ltd Merlin Biosciences Fund III Decontamination services provider |
 | De Novo Pharmaceuticals Ltd Merlin Biosciences Fund In silico structure-based drug design |
 | DestinationSkin Ltd Merlin Biosciences Fund III Skin treatment and hair removal |
 | Energist Ltd Merlin Biosciences Fund III Variable pulsed light therapy |
 | EpiCept Inc Merlin Biosciences Fund Topical pain management IPO in January 2006 |
 | Intercytex Group plc Merlin Biosciences Fund Hair and tissue regrowth IPO in February 2006 |
 | Lab 21 Ltd Merlin Biosciences Fund III Clinical diagnostics and monitoring |
 | LiDCO Group plc Merlin Biosciences Fund Cardiac output monitors IPO in June 2004 |
 | Neurotech Inc Merlin Biosciences Fund Cell-based drugs for diseases of the eye |
 | Noxxon Pharma AG Merlin Biosciences Fund Mirror image oligonucleotide drugs |
 | Onyvax Ltd Merlin Biosciences Fund Whole-cell allogenic vaccines for cancer |
 | PanTherix Ltd Merlin Biosciences Fund, Merlin Fund Novel broad-spectrum antibiotics |
 | Plethora Solutions Holdings plc Merlin Biosciences Fund III Discovering and developing urological products IPO in March 2005 |
 | ReNeuron Group plc Merlin Biosciences Fund, Merlin Fund Treatments for neurological disorders IPO in August 2005 |
 | Santhera Pharmaceuticals AG Merlin Biosciences Fund Small molecule therapeutics for neuromuscular and metabolic diseases IPO in November 2006 |
 | Sosei Co. Ltd Merlin Biosciences Fund Identifying new uses for established drugs Arakis merged with Sosei Co in August 2005 |
 | Vectura Group plc Merlin Biosciences Fund Drug formulations and devices for respiratory diseases IPO in July 2004 |
 | Virgin Health Bank Ltd Merlin Biosciences Fund III Cord blood banking |
 | VivoMedica plc Merlin Biosciences Fund III Advancing medical devices from prototype to market Reversal in to AIM listed company in July 2005 |
 | Wilex AG Merlin Biosciences Fund Antibody and small molecule cancer therapies IPO in November 2006 |
 | York Pharma plc Merlin Biosciences Fund III Acquisition, development and commercialisation of prescription dermatological products Acquisition of Fund III company Derms Development by York Pharma in October 2007 |
